

# Susannah A Jacob

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8451786/publications.pdf>

Version: 2024-02-01

41  
papers

2,618  
citations

448610

19  
h-index

340414

39  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3710  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 7-14.	0.9	0
2	The value of first-line chemotherapy and targeted therapy in the treatment of breast cancer. <i>European Journal of Cancer Care</i> , 2021, 30, e13352.	0.7	4
3	Assessing tumor centrality in lung stereotactic ablative body radiotherapy (SABR): the effects of variations in bronchial tree delineation and potential for automated methods. <i>Medical Dosimetry</i> , 2021, 46, 94-101.	0.4	4
4	Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis. <i>Lancet Oncology</i> , The, 2021, 22, 173-181.	5.1	8
5	Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. <i>Lancet Oncology</i> , The, 2021, 22, 182-189.	5.1	47
6	Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. <i>JCO Global Oncology</i> , 2021, 7, 1074-1083.	0.8	3
7	Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. <i>Lancet Oncology</i> , The, 2019, 20, 769-780.	5.1	128
8	Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines. <i>Radiotherapy and Oncology</i> , 2016, 118, 118-121.	0.3	10
9	Estimation of an Optimal Chemotherapy Utilisation Rate for Upper Gastrointestinal Cancers: Setting an Evidence-Based Benchmark for the Best-Quality Cancer Care. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-10.	0.7	4
10	Estimation of an Optimal Chemotherapy Utilisation Rate for Cancer: Setting an Evidence-based Benchmark for Quality Cancer Care. <i>Clinical Oncology</i> , 2015, 27, 77-82.	0.6	9
11	Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. <i>Radiotherapy and Oncology</i> , 2014, 112, 140-144.	0.3	387
12	Estimation of the Optimal Brachytherapy Utilization Rate in the Treatment of Gynecological Cancers and Comparison With Patterns of Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 400-405.	0.4	10
13	Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 483-489.	0.9	6
14	A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. <i>Breast</i> , 2012, 21, 562-569.	0.9	8
15	A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia) with models of "optimal" therapy. <i>Breast</i> , 2012, 21, 570-577.	0.9	14
16	Chemotherapy in Rectal Cancer: Variation in Utilization and Development of an Evidence-based Benchmark Rate of Optimal Chemotherapy Utilization. <i>Clinical Colorectal Cancer</i> , 2011, 10, 102-107.	1.0	6
17	Estimation of an Optimal Chemotherapy Utilisation Rate for Primary Malignant Brain Tumours: an Evidence-based Benchmark for Cancer Care. <i>Clinical Oncology</i> , 2011, 23, 48-54.	0.6	4
18	Estimation of an Optimal Utilisation Rate for Palliative Radiotherapy in Newly Diagnosed Cancer Patients. <i>Clinical Oncology</i> , 2010, 22, 56-64.	0.6	26

#	ARTICLE	IF	CITATIONS
19	Estimation of an optimal chemotherapy utilisation rate for lung cancer: An evidence-based benchmark for cancer care. <i>Lung Cancer</i> , 2010, 69, 307-314.	0.9	19
20	Estimation of an optimal chemotherapy utilisation rate for breast cancer: Setting an evidence-based benchmark for the best-quality cancer care. <i>European Journal of Cancer</i> , 2010, 46, 703-712.	1.3	15
21	Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: Setting an evidence-based benchmark for the best-quality cancer care. <i>European Journal of Cancer</i> , 2009, 45, 2150-2159.	1.3	7
22	Estimation of an optimal chemotherapy utilisation rate for colon cancer: An evidence-based benchmark for cancer care. <i>European Journal of Cancer</i> , 2009, 45, 2503-2509.	1.3	5
23	Estimation of Optimal Brachytherapy Utilization Rate in the Treatment of Malignancies of the Uterine Corpus by a Review of Clinical Practice Guidelines and the Primary Evidence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 849-858.	0.4	5
24	Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines. <i>Cancer</i> , 2006, 106, 453-465.	2.0	12
25	Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix. <i>Cancer</i> , 2006, 107, 2932-2941.	2.0	20
26	Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. <i>Cancer</i> , 2005, 103, 383-392.	2.0	15
27	Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. <i>Cancer</i> , 2005, 103, 393-401.	2.0	33
28	Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. <i>Cancer</i> , 2005, 103, 462-473.	2.0	38
29	Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. <i>Cancer</i> , 2005, 103, 2216-2227.	2.0	38
30	The role of radiotherapy in cancer treatment. <i>Cancer</i> , 2005, 104, 1129-1137.	2.0	1,279
31	Comparison of face-to-face and videoconferenced multidisciplinary clinical meetings. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2004, 48, 487-492.	0.6	48
32	Estimation of an optimal radiotherapy utilization rate for melanoma. <i>Cancer</i> , 2004, 100, 1293-1301.	2.0	40
33	Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma. <i>Cancer</i> , 2004, 101, 657-670.	2.0	27
34	Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma. <i>Cancer</i> , 2004, 101, 671-681.	2.0	45
35	Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma. <i>Cancer</i> , 2004, 101, 682-692.	2.0	34
36	Waiting times for radiotherapy—a survey of patients' attitudes. <i>Radiotherapy and Oncology</i> , 2004, 70, 283-289.	0.3	23

#	ARTICLE	IF	CITATIONS
37	Estimation of an optimal radiotherapy utilization rate for breast carcinoma. <i>Cancer</i> , 2003, 98, 1977-1986.	2.0	79
38	Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2003, 47, 274-278.	0.6	22
39	O-120 Estimating an optimal radiotherapy utilisation rate for lung cancer based upon evidence-based treatment guidelines. <i>Lung Cancer</i> , 2003, 41, S38.	0.9	0
40	A model for decision making for the use of radiotherapy in lung cancer. <i>Lancet Oncology</i> , The, 2003, 4, 120-128.	5.1	101
41	Palliative radiotherapy of bone metastases: an evaluation of outcome measures. <i>Journal of Evaluation in Clinical Practice</i> , 2001, 7, 47-64.	0.9	35